Erlmeier Franziska, Ivanyi Philipp, Hartmann Arndt, Autenrieth Michael, Wiedemann Max, Weichert Wilko, Steffens Sandra
Institute of Pathology, Technical University Munich (TUM), Trogerstraße 18, 81675, Munich, Germany.
German Renal Cell Tumor Consortium, Jena, Germany.
Med Oncol. 2017 Feb;34(2):15. doi: 10.1007/s12032-016-0874-1. Epub 2016 Dec 29.
c-Met plays a role as a prognostic marker in clear cell renal cell carcinoma. In addition, recently the tyrosine kinase inhibitor cabozantinib targeting c-Met was approved for the treatment of advanced renal cell carcinoma (RCC). In contrast to clear cell RCC, little is known about c-Met expression patterns in rarer RCC subtypes. The aim of this study was to evaluate the prevalence, distribution and prognostic impact of c-Met expression on chromophobe (ch)RCC. Patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimens were analyzed for c-Met expression by immunohistochemistry. Expression data were associated with clinicopathological parameters including patient survival. Eighty-one chRCC patients were eligible for analysis. Twenty-four (29.6%) patients showed a high c-Met expression (c-Met, staining intensity higher than median). Our results showed an association between c-Met expression and the existence of lymph node metastasis (p = 0.007). No further significant clinicopathological associations with c-Met were identified, also regarding c-Met expression and overall survival. In conclusion, to our knowledge this is the first study evaluating the prognostic impact of c-Met in a considerably large cohort of chRCC. High c-Met expression is associated with the occurrence of lymph node metastasis. This indicates that c-Met might be implicated into metastatic progression in chRCC.
c-Met在透明细胞肾细胞癌中作为一种预后标志物发挥作用。此外，最近靶向c-Met的酪氨酸激酶抑制剂卡博替尼被批准用于治疗晚期肾细胞癌（RCC）。与透明细胞RCC不同，对于较罕见的RCC亚型中c-Met的表达模式知之甚少。本研究的目的是评估c-Met表达在嫌色性（ch）RCC中的发生率、分布及预后影响。对因chRCC接受肾脏手术的患者进行回顾性评估。通过免疫组织化学分析肿瘤标本中c-Met的表达。表达数据与包括患者生存情况在内的临床病理参数相关。81例chRCC患者符合分析条件。24例（29.6%）患者显示c-Met高表达（c-Met，染色强度高于中位数）。我们的结果显示c-Met表达与淋巴结转移的存在之间存在关联（p = 0.007）。未发现与c-Met进一步显著的临床病理关联，c-Met表达与总生存情况方面也是如此。总之，据我们所知，这是第一项在相当大的chRCC队列中评估c-Met预后影响的研究。c-Met高表达与淋巴结转移的发生相关。这表明c-Met可能参与了chRCC的转移进展。
